Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.

Rajiv AgarwalStefan D AnkerGerasimos FilippatosBertram PittEllen BurgessLuis M RuilopeJohn BoletisRobert TotoGuillermo E UmpierrezChristoph Wanner Takashi WadaCharlie ScottAmer JosephIke OgbaaLuke RobertsMarkus F ScheererGeorge L Bakris

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)

This analysis highlights the pitfalls of direct comparisons between trials. When key differences in trial design are considered, FIDELIO-DKD and CREDENCE demonstrate cardiorenal benefits of a similar magnitude.

Keyphrases

study protocol
clinical trial
phase iii
randomized controlled trial
metabolic syndrome
skeletal muscle
open label
weight loss